Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial

European Urology

Volumn 63, Issue 2, 2013, Pages 283-295

  Khullar, Vik ^a   Amarenco, Gerard ^b   Angulo, Javier C ^c   Cambronero, Javier ^d   Høye, Kjetil ^e   Milsom, Ian ^f   Radziszewski, Piotr ^g   Rechberger, Tomasz ^h   Boerrigter, Peter ⁱ   Drogendijk, Ted ⁱ   Wooning, Marianne ⁱ   Chapple, Christopher ^j  

^a ST MARY S HOSPITAL   (United Kingdom)

^b HÔPITAL TENON   (France)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e Medi3 Innlandet AS   (Norway)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h MEDICAL UNIVERSITY OF LUBLIN   (Poland)

ⁱ Astellas Pharma Global Development   (Netherlands)

^j ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

more..

Author keywords

3 Adrenoceptor agonist; Mirabegron; Overactive bladder (OAB)

Indexed keywords

MIRABEGRON; PLACEBO; TOLTERODINE;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; URINARY TRACT INFECTION; URINE INCONTINENCE; VITAL SIGN; XEROSTOMIA;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; AGED; AUSTRALIA; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUALITY OF LIFE; QUESTIONNAIRES; SINGLE-BLIND METHOD; THIAZOLES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URINATION;

EID: 84871925684     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.10.016     Document Type: Article

References (16)

1. D.E. Irwin, Z.S. Kopp, B. Agatep, I. Milsom, and P. Abrams Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction BJU Int 108 2011 1132 1138
2. D.E. Irwin, I. Milsom, and S. Hunskaar Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 2006 1306 1315 discussion 1314-5 (Pubitemid 44692945)
3. K.S. Coyne, C.C. Sexton, and C.L. Thompson The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study BJU Int 104 2009 352 360
4. C.R. Chapple, V. Khullar, Z. Gabriel, D. Muston, C.E. Bitoun, and D. Weinstein The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 2008 543 562
5. O. Yamaguchi, O. Nishizawa, and M. Takeda Clinical guidelines for overactive bladder Int J Urol 16 2009 126 142
6. A.O. D'Souza, M.J. Smith, L.A. Miller, J. Doyle, and R. Ariely Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 2008 291 301 (Pubitemid 351711980)
7. J.S. Benner, M.B. Nichol, and E.S. Rovner Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 2010 1276 1282
8. V. Kumar, L. Templeman, C.R. Chapple, and R. Chess-Williams Recent developments in the management of detrusor overactivity Curr Opin Urol 13 2003 285 291 (Pubitemid 36900667)
9. 3-adrenoceptors in human detrusor muscle Urology 59 5Suppl 1 2002 25 29
10. E.H. Ohlstein, A. von Keitz, and M.C. Michel A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder Eur Urol 62 2012 834 840
11. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. In press. http://dx.doi.org/10.1111/j.1464-410X.2012.11023.x.
12. L. Linnér, H. Schiöler, E. Samuelsson, I. Milsom, and F. Nilsson Low persistence of anticholinergic drug use in Sweden Eur J Clin Pharmacol 67 2011 535 536
13. M. Schiffers, P. Sauermann, B. Schurch, and U. Mehnert The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects World J Urol 28 2010 651 656
14. B. Olshansky, U. Ebinger, J. Brum, M. Egermark, A. Viegas, and L. Rekeda Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ≥50 years J Cardiovasc Pharmacol Ther 13 2008 241 251
15. K.E. Andersson, and B. Olshansky Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations BJU Int 100 2007 1007 1014 (Pubitemid 47537647)
16. S. Lee, B. Malholtra, D. Creanga, M. Carlsson, and P. Glue A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder BMC Med Res Methodol 9 2009 55